Aline Plançon, assistant director of Interpol's medical products counterfeiting and pharmaceutical crime sub-directorate, tells CNBC that the largest fake pharmaceutical markets are in Asia and Latin America.
Chinese authorities have visited a site operated by Danish drugmaker Novo Nordisk, the latest evidence of a widening investigation into Western drugmakers.
Leonard Schleifer, Regeneron Pharmaceuticals president and CEO, breaks down the company's better-than-expected earnings, and positive results from its phase three trials of a drug designed to improve vision in patients with diabetic macular edema.
Alex Rodriguez was suspended through 2014 and All-Stars Nelson Cruz, Jhonny Peralta and Everth Cabrera were banned 50 games apiece Monday when Major League Baseball disciplined 13 players in a drug case.
Procter & Gamble posts earnings of 79 cents a share vs. 77 cents estimate.
Barbara Ryan, FTI Consulting, breaks down the second quarter numbers on Pfizer and Merck and provides an outlook on which companies have the best drugs in the pipeline.
Merck reported second-quarter earnings on Tuesday that exceeded analysts' expectations, yet revenues fell on weak drug sales.
Pfizer reported earnings slightly ahead of forecasts, as the largest U.S. drugmaker lines up a business split that could lead to the spin-off of its generics division.
Regardless of what narrative may ultimately prove to best explain GSK's current problems in China, doing business in the sector for multinationals will never be the same.
Both Pfizer and Merck are expected to report double-digit declines in top- and bottom-line growth when they announce earnings Tuesday.
Barbara Ryan, FTI Consulting, provides a preview of Pfizer and Merck's earnings, and discusses how both pharma giants have improved shareholder value through M&A.
U.S. generic drugmaker Perrigo agreed to buy fellow drug company Elan for $8.6 billion on Monday in a deal that will hand it royalty rights from a blockbuster treatment and tax savings from being domiciled in Ireland.
In a recent report, researchers found that blood pressure medication also functions to provide measurable relief for patients experiencing worsening Alzheimer's symptoms.
Daniel O'Day, CEO of Roche, talks about the company's results for the first half of the year and sales of its new breast cancer drugs.
Daniel O'Day, CEO of Roche's pharma unit, declines to comment on Alexion deal talks, but says the company is keen on incorporating innovations into its portfolio.
The chief executive of GlaxoSmithKline said the allegations of bribery and corruption in China were "deeply disappointing," as the company reported second-quarter results.
Glaxo's problems may go beyond the sales practices that are currently at the center of a bribery and corruption scandal in China. They may extend to its Shanghai research and development center.
British drug giant, GlaxoSmithKline admitted that some of its executives in China appear to have violated Chinese law in a bribery and corruption scandal.
GlaxoSmithKline CEO Andrew Witty will detail this week what action the drugmaker is taking in response to allegations of bribery against it in China, sources said.
China detained and questioned an executive of GlaxoSmithKline, amid an ongoing bribery investigation, reports CNBC's Eunice Yoon.